NASDAQ:QNTM Quantum Biopharma Q3 2025 Earnings Report $3.85 -0.15 (-3.75%) Closing price 04:00 PM EasternExtended Trading$3.88 +0.03 (+0.81%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Quantum Biopharma EPS ResultsActual EPS-$1.25Consensus EPS -$0.20Beat/MissMissed by -$1.05One Year Ago EPSN/AQuantum Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$2.89 millionBeat/MissN/AYoY Revenue GrowthN/AQuantum Biopharma Announcement DetailsQuarterQ3 2025Date11/7/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsQuantum Biopharma's next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Quantum Biopharma Earnings HeadlinesQuantum BioPharma Licensee Unbuzzd Taps New CEO Ahead of Planned Listing3 hours ago | theglobeandmail.comQuantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing3 hours ago | markets.businessinsider.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 25 at 1:00 AM | Stansberry Research (Ad)Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEOSeptember 24 at 8:00 AM | globenewswire.comQuantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis TreatmentsSeptember 23 at 4:19 PM | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis TreatmentsSeptember 23 at 4:19 PM | markets.businessinsider.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) Inc. (NASDAQ:QNTM), formerly known as FSD Pharma Inc., is a biotechnology company developing therapeutics for neurodegenerative and other serious medical conditions. The company’s research pipeline is centered on novel small-molecule compounds intended to address diseases involving myelin damage and related neurological dysfunction. Its lead investigational program, Lucid-MS, is being developed as a potential treatment for multiple sclerosis. The compound is designed to target processes associated with demyelination and may also support remyelination, although it remains under development and has not been approved for commercial use. Quantum BioPharma has also pursued research related to alcohol use disorder and other central nervous system conditions. The company has additionally been involved in consumer health initiatives through products such as UNBUZZD, a functional beverage marketed for use after alcohol consumption. Quantum BioPharma is based in North America and has historically operated across the Canadian and U.S. biotechnology and capital markets. The company adopted its current name from FSD Pharma as part of a broader strategic repositioning toward biotechnology and pharmaceutical development.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
